---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-048907"
form_type: "8-K"
ticker: "SIGA"
cik: "0001010086"
company_name: "SIGA TECHNOLOGIES INC"
filed_at: "2024-12-10T23:59:59+00:00"
generated_at: "2026-05-29T04:58:50.772926+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# SIGA's tecovirimat fails mpox lesion resolution endpoint; STOMP enrollment stopped

## Summary
- Tecovirimat did not improve time to lesion resolution vs placebo in mild to moderate clade II mpox; DSMB recommended stop enrollment.
- Enrollment halted in all study arms including open-label for severe patients; data analysis ongoing for secondary endpoints.
- Safety profile affirmed as comparable to placebo, consistent with prior studies over 15 years.
- CEO stated ~75% of randomized patients received drug >5 days after symptom onset; early treatment may offer benefit.
- Company expects three ongoing trials (UNITY, Platinum-CAN, EPOXI) to yield similar results given design parallels.

## SEC filing metadata
- accession: 0001140361-24-048907
- form_type: 8-K
- ticker: SIGA
- cik: 0001010086
- company_name: SIGA TECHNOLOGIES INC
- filed_at: 2024-12-10T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1010086/000114036124048907/0001140361-24-048907-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1010086/000114036124048907/ef20039836_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-048907
- JSON: https://secwatch.observer/filing/0001140361-24-048907.json
- Plain text: https://secwatch.observer/filing/0001140361-24-048907.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.